HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement Firm Takes Stab At Nutricosmetics With Skin Perfect Launch

This article was originally published in The Rose Sheet

Executive Summary

Skin Perfect Anti-Aging With Collagen and Skin Perfect Hair, Skin and Nails each cost $130 for a three-month supply from supplement firm Purity Select’s new sister company. According to Skin Perfect, the products are more efficacious than other nutricosmetics due to high levels of active ingredients.

You may also be interested in...



Nutricosmetics In U.S. On The Rise; Savvy Marketing Could Spur Uptake

At the SupplySide West conference and trade show in Las Vegas Nov. 7-8, industry experts shared their insights on the nutricosmetics market and offered advice for firms looking to attract consumers to the space.

No To Grapefruit Mask? Natural Player Yes To, Inc. Issues Recall Following ‘Chemical Burn’ Reports

Yes To is investigating reports – including posts on leading social media platforms – regarding irritation and redness experienced by children and other users of its Yes To Grapefruit Glow-Boosting Unicorn Paper Mask. In the meantime, the company is recalling the product voluntarily.

Federal Court Stays Class Action Against CBD Firm Green Roads To Await FDA Rulemaking

Plaintiffs against Florida-based Green Roads used certificates of analysis the company makes freely available to consumers to determine that batches of two of the company’s products contained “significantly” less cannabidiol versus labeled amounts. A Florida federal court rejected the firm’s motion to dismiss, but it is interested in seeing how FDA rulemaking develops.

UsernamePublicRestriction

Register

RS019139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel